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Abstract
OBJECTIVE: To compare the curative effects of
heat-sensitive moxibustion with conventional
drugs on chronic persistent asthma and seek a valu-
able therapy to replaceWestern Medicine.
METHODS: The participants in this multi-center,
randomized, and controlled study were randomly
divided into two groups: group A (n=144), treated
with heat-sensitive moxibustion (50 sessions) and
group B (n=144), treated with Seretide (salmeterol
50 μg/fluticasone 250 μg, twice a day). The scores
of asthma control test (ACT), forced expiratory vol-
ume in 1 second (FEV1), peak expiratory flow (PEF),
and attack frequency were measured after 15, 30,
60, and 90 days of treatment. Patients followed up
3 and 6 months after treatment.
RESULTS: There was a significant difference (P=
0.0002) in the ACT score and lung function be-
tween the two groups after 3 months of treatment
and (P=0.000 03) during the follow-up visits. In ad-
dition, heat-sensitive moxibustion reduced attack
frequency in the period from inclusion to the
6-month follow-up visit.
CONCLUSION: This study shows that heat-sensitive
moxibustion may have a comparable curative effect
toSeretide(salmeterol/fluticasone) on asthma.
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INTRODUCTION
Bronchial asthma is a signiﬁcant burden on healthcare
and the social economy.1-5 In 2010, there were 300 mil-
lion asthma patients worldwide.6 At present, no sin-
gle therapy can effectively cure it. Therefore, asthma
treatment aims to control the disease and improve
the quality of life.7,8
Western Medicine can cause discomfort and influence
daily life.9 Therefore, acupuncture or moxibustion has
been gradually accepted as a complementary or alterna-
tive treatment in China and Western countries for pre-
venting asthma attacks and relieving symptoms.10-12
Heat-sensitive moxibustion is a new therapy in which a
burning moxa-roll is placed over a heat-sensitive acu-
point.13 Studies have shown that it can treat diseases
such as myofascial pain syndrome,14 lumbar disc hernia-
tion,15 pressure sores,16 knee osteoarthritis,17 primary
dysmenorrhea,18 neck pain,19 and allergic rhinitis.20
We have found that moxibustion over heat-sensitive
acupoints on the back of asthma patients21,22 can im-
prove their clinical asthma symptoms.23,24 Two trials
suggesting that heat-sensitive moxibustion can treat
asthma23,24 were not randomized and controlled trials
with large sample sizes.
Therefore, we designed this rigorous trial to provide ev-
idence to confirm the curative effect of heat-sensitive
moxibustion on chronic persistent asthma. Heat-sensi-
tive moxibustion could be a valuable asthma-control-
ling therapy to replace Western Medicine. The de-
signed plan of this study was published in Trials in Oc-
tober 2010.25
DATA ANDMETHODS
Estimation of sample size
We estimated the sample size according to the require-
ments of a non-inferiority clinical trial. Non-inferiority
critical value δ was determined with a small sample pi-
lot study. ACT score after 3 months of treatment was
used as the terminal index. The difference in means be-
tween the two groups was 0.45. Considering clinical
relevance and statistical judgment, δ=0.15 (30% of Δ).
We calculated that 120 patients (α=0.05, β=0.2) were
needed. Allowing for a 20% loss, 144 participants were
required in each group, with 288 participants in total.
Randomization
Central randomization used in this trial was performed
by the China Academy of Chinese Medical Sciences
(Beijing, China). Patients meeting the inclusion criteri-
on were randomly and equally divided into two
groups. Before randomization, the patients gradually
stopped medication and were routinely nursed for
asthma.
Ethics
The ethics committee of the Hospital Affiliated to Ji-
angxi Institute of Traditional Chinese Medicine ap-
proved this trial with the code 2008 (13).
Inclusion criterion
Patients meeting the asthma-diagnosing standard ac-
cording to the guideline of asthma treatment and pre-
vention in China (GATPC)24 were grouped into three
categories: acute exacerbation, chronic persistence, and
clinical remission. GATPC severity includes intermit-
tent, mild, moderate, and severe grades. Our trial only
chose patients with chronic moderate persistent asth-
ma. All patients aged 18-65 years provided written in-
formed consent. Moreover, heat-sensitivity appeared
within the rectangular area consisting of the two outer
lines of the dorsal Bladder Meridian of Foot-Taiyang
and two horizontal lines of Fei Shu (BL 13) and Geshu
(BL 17), 6 inches from the intercostals space between
the first rib and second rib of the anterior aspect of the
chest. Patients were asked to take no medicine during
the treatment and acknowledge acceptance of treat-
ment and related inquiries 24 h before and after treat-
ment.
Exclusion criterion
Patients with one of the following conditions were ex-
cluded: (a) other diseases that also cause breathlessness
or dyspnea, such as bronchiectasis, cor pulmonale, pul-
monary fibrosis, tuberculosis, pulmonary abscess, and
chronic obstructive pulmonary disease; (b) pregnancy
or lactation; (c) hormone-dependent patients, or pa-
tients using adrenal cortical hormone within 4 weeks
of recruitment; (d) life-threatening complications, such
as cerebrocardiovascular diseases, diseases of liver, kid-
ney, and hematopoietic system; and (e) psychotic pa-
tients.
Baseline data
Two hundred and thirty of 518 patients in our trial
from September 2008 to December 2010 were exclud-
ed from the study (Figure 1). According to the deﬁniti-
on of intention-to-treat (ITT), the ITT population
comprised 288 patients in the twelve hospitals. The
groups were comparable in baseline characteristics (Ta-
ble 1), including the objective parameters of age, sex,
duration of asthma, and ACT scores. There were no
statistically significant differences between the two
groups (P>0.05).
Data collection
Assessors, who did not participate in the treatment and
were blind to the allocation results, performed the
outcome assessment. The statistician conducting the
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analyses remained blind to treatment group. Data were
made public once they were summarized and analyzed.
Treatment
The treatment plan in this study was developed over a
3-month period. Patients were randomly divided into a
heat-sensitive moxibustion group (treatment group)
and a control group. In the treatment group, all acu-
points were stimulated with the burning of
moxa-sticks, 22 mm in diameter and 160 mm in
length, (produced by Jiangxi Hospital of Traditional
Chinese Medicine, China). Patients lay in a comfort-
able position with the moxibustion site fully exposed
in a room at 24℃-30℃.
Heat-sensitive moxibustion
An ignited moxa-stick was held over the rectangular ar-
ea consisting of two outer lines of the dorsal Bladder
Meridian of Foot-Taiyang and two horizontal lines of
Feishu (BL 13) and Geshu (BL 17), 6 inches from the
intercostal space between the first rib and second rib of
the anterior aspect of the chest. The burning
moxa-stick was held about 3 cm from the skin to look
for heat-sensitive acupoints. When patients felt the
heat penetrating to deep tissue or spreading to the sur-
rounding area or transmitting in a direction, the thera-
pists marked the point as having a heat-sensitive phe-
nomenon. Therapists attempted to find all heat-sensi-
tive acupoints in each patient.
Assessed for eligibility
(n=518)
Completed 3-month
assessment (n=138)
Withdrawal (n=6)
Protocol violation (n=1)
Withdrew consent (n=2)
Lost to follow up (n=2)
Reason unclear (n=1)
Not randomly assigned
(n=230)
Not Eligible
(n=180)
Decline to participate
(n=32)
Other reasons (n=18)
Randomly assigned patients
(n=288)
Central random
allocation
Assigned to receive
heat-sensitive moxibustion
(n=144)
Assessed at baseline
(n=144)
Declined at baseline assessment
(n=0)
Assigned to receive conventional medicine
(n=144)
Assessed at baseline
(n=144)
Declined at baseline assessment
(n=0)
Completed 3-month
assessment (n=139)
Withdrawal (n=5)
Withdrew consent (n=1)
Lost to follow up (n=3)
Adverse effect (n=1)
Withdrew consent
(n=2)
Lost to follow up (n=2)
Lost to follow up (n=1)
Figure 1 Diagram for procedure of the trial
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Having found all heat-sensitive acupoints possible,
therapists treated patients at the acupoint most sensi-
tive to heat until the patient nearly felt the disappear-
ance of the heat-sensitivity. The heat-sensitivity tended
to decrease but could be still identified even at the end
of treatment. After treatment, the therapist recorded
the duration of moxibustion. During the first month,
patients were treated once a day in the first 8 days and
12 times in the following 22 days. The treatment was
given 15 times a month in the remaining two months.
Control group (Seretide)
Seretide Accuhaler (GlaxoSmithKline Plc, UK), con-
taining fluticasone propionate and salmeterol xin-
afoate, is recommended by Global Initiative for Asth-
ma (GINA) as a regular treatment of asthma.26 In our tri-
al, patients were treated with Seretide (salmeterol 50 μg/
fluticasone 250 μg) twice a day for 90 days.
Index of observation
ACT score, a primary index of observation, was
measured before treatment and after 15, 30, 60,
and 90 days of treatment. ACT, recommended by
GINA in 2002,7 is a validated and patient-completed
measurement of asthma control comprising five ques-
tions on limitation of activity, difficulty in breathing,
symptoms at night, use of drugs and frequency of at-
tack over the previous four weeks. The questions are
scored from 1 (worst) to 5 (best), and the ACT score is
the sum of the responses, giving the maximum score of
25. The ACT in Chinese, provided by China Asthma
Alliance in 2006,26 was tested by Chinese researchers
previously. Some studies suggested that the score sys-
tem was useful for identifying patients in China.27,28
Secondary indexes of observation were forced expirato-
ry volume in 1 second (FEV1), peak expiratory flow
(PEF), and frequency of attack. All patients filled in
asthma diaries during 3 weeks before randomization
and every visit after randomization. In the diaries they
documented the time of attack from beginning to end,
the intensity, the frequency, and the associated symp-
toms during each asthma attack. Patients documented
whether or not they took medicine during treatment
periods. If they did, they were required to document
its name and dosage, the time of administration, the
time of the relief of the symptoms and the side-effects
Table 1 Baseline characteristics of patients with chronic moderate persistent asthma
Item
Age [mean (SD), years]
Age
Sex [n (%)]
Patient source [n (%)]
History of asthma [n (%)]
Body mass index [mean (SD) (kg/m2)]
ACT [mean (SD)]
Baseline FEV1 [mean (SD) (L)]
Baseline PEF [mean (SD) (m/s)]
Attack frequency [mean (SD) (/w)]
Prior ICS use [n (%)]
ICS + LABA [n (%)]
Age (min-max, years)
Age>50 years [n (%)]
Male
Female
Specialized outpatient center
Primary care
<5 year
5-10 year
>10 year
Beclomethasone
Budesonide
Ciclesonide
Fluticasone
Mometasone
Budesonide/formoterol
Fluticasone/salmeterol
Experimental group
43.8 (13.00)
18-65
51 (35.42)
58 (40.28)
86 (59.72)
108 (37.50)
40 (13.89)
63 (43.75)
40 (27.78)
41 (28.47)
23.07 (2.31)
15.10 (4.05)
74.90 (16.70)
72.81 (22.25)
4.53 (1.02)
33 (22.92)
30 (20.83)
6 (4.17)
27 (18.75)
8 (5.56)
30 (20.83)
10 (6.94)
Control group
43.6 (12.2)
20-65
50 (34.72)
62 (43.06)
82 (56.94)
110 (38.19)
30 (10.42)
69 (47.92)
45 (31.25)
30 (20.83)
21.53 (2.13)
15.70 (3.78)
75.10 (18.50)
73.83 (24.33)
4.36 (1.13)
29 (20.14)
27 (18.75)
4 (2.78)
53 (36.81)
6 (4.17)
20 (13.89)
5 (3.47)
Notes: experimental group was treated with heat-sensitive moxibustion; control group was treated with fluticasone/salmeterol (Seretide).
ACT: asthma control test; FEV1: forced expiratory volume in 1 second; PEF: peak expiratory flow; IICS: inhaled corticosteroid, LABA:
long-acting β2-agonist.
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of the medicine. Adverse reactions were recorded dur-
ing the 3-month treatment and 6-month follow-up visit.
Quality monitoring
Monitoring the quality of moxibustion is mainly based
on quality control program (QCP) including the de-
sign of case report form (CRF) and the training of
qualified investigators, researchers and data-managers.29
According to good clinical practice (GCP), a standard
QCP was established to monitor the quality of our tri-
al. Monitors directly appointed by the project leader
completed the quality control program, guaranteed da-
ta accuracy, and prevented or detected plan violations.
Clinical centers and clinicians, the randomization sys-
tem of the centers, and the treatment processes were
monitored. In addition, the case report forms were re-
viewed for completeness and internal consistency, the
eligibility and validity of the patients in the study were
verified, and data were monitored for compliance and
accuracy.
Compliance analysis
In the control group, data were collected with an elec-
tronic timed inhaler (Nebulizer Chronolog), which can
automatically count and record each actual inhaled dos-
age. The testees were given an initialized Nebulizer
Chronolog and a diary card used to record their daily
symptoms. The card included instructions on how to
use the inhaler. After 3 months of treatment, the Nebu-
lizer Chronolog and diary cards were returned. Days of
good compliance were defined as days a patient took a
fixed dosage of drug at the appropriate time.
Patients' compliance to receiving heat-sensitive moxi-
bustion was assessed with three oral questions: "Does
the patient receive moxibustion treatment in hospital
regularly?" "Has the patient ever had any history of not
using moxibustion treatment?" "Does the patient still
receive last prescribed moxibustion?" The higher the
score, the better the compliance.
Statistical analysis
The intention-to-treat (ITT) population is defined as
the randomized patients. The data analysis of baseline
characteristics is based on the ITT population as well
as the primary and secondary indexes. In the ITT pop-
ulation, none of the patients were excluded and the pa-
tients were analyzed according to the randomization
scheme. The basic ITT principle was that patients in
the trials should be analyzed, regardless of whether
they receive or adhere to treatment.
Data were analyzed with SAS 9.0 statistical software
(Cary, NC, USA). The first step of analysis was to com-
pare baseline characteristics between the two groups.
The second step was to check whether the treatment
group was inferior or not to the control group in treat-
ing asthma.
For data in a normal distribution (normality, homoge-
neity of variances), repeated analyses were used in as-
sessments. Mann-Whitney U, t-test, and Wilcoxon test
were used for comparison of variables. Two-sided test
was applied to all available data, and P value <0.05 was
considered statistically significant. Missing data were re-
placed according to the principle of the last observation.
RESULTS
ACT score
There was an obvious difference (P<0.001) in ACT
score at each time-point as compared to baseline. Com-
parisons of data at six time-points between groups were
multiple testing. We used the Bonferroni adjustment
t-test.30 The differences in ACT score between the two
groups at each time-point are shown in Table 2, indi-
cating significant differences in the ACT score after 3
months of treatment (P=0.0002) and highly significant
difference during the 6-month follow-up visit (P=
0.000 03). Figure 2 shows that the mean ACT score of
both groups increased sharply after half a month of
treatment and continually increased up to the end of
6-month follow-up visit. In the control group, the
ACT score remained stable during 3- and 6-month fol-
low-up visit, and patients continued to take the drug
with gradually reduced dosage during follow-up visit.
Lung function
Tables 3 and Table 4 show the secondary indexes of
FEV1, PEF, and attack frequency derived from ITT
analyses. FEV1 and PEF in both groups after 3 months
of treatment were much higher than those before treat-
ment (Table 3). The improvement of lung function in
the heat-sensitive moxibustion group was better than
that in the control group (P=0.035 for FEV1, P=0.011
for PEF). Moreover, there were noticeable differences
between the two groups during the 6-month follow-up
visit (P=0.042 for FEV1, P=0.0012 for PEF). The fre-
quency of asthma attack after 3 months of treatment in
the heat-sensitive moxibustion group was much lower
than that in the control group (P=0.000 17). There
was still an obvious difference between the two groups
during 6-month follow-up visit (P=0.047).
In the control group, the majority of patients were able
to correctly use the inhaler. The days of inhaling inade-
quate dosage accounted for 9% and the days of inhal-
ing excessive dosage accounted for 2%. In the heat-sen-
sitive moxibustion group, 90% of patients were regular-
ly treated in hospitals, and only 1.5% of patients were
irregularly treated.
Adverse reactionsAmong the 9 patients (5.1% ) with
mild adverse reactions during treatment were 5 cases of
headache and 4 cases of palpitation. However, after the
treatment, all the symptoms disappeared. No patient
reported any severe adverse reactions.
DISCUSSION
This trial used subjective and objective indexes to as-
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sess curative effect on asthma using standard treatment
or heat-sensitive moxibustion. ACT score was marked-
ly enhanced in both groups, there was an obvious dif-
ference in ACT score and lung function between the
two groups, and asthma attack frequency was notice-
ably lower in the heat-sensitive moxibustion group.
This indicates that heat-sensitive moxibustion is not in-
ferior to Seretide in curative effect on bronchial asthma.
In contrast to acupuncture, heat-sensitive moxibustion
indirectly stimulates acupoints. Adverse reactions, such
as infection, minor hemorrhage and pain in the moxi-
bustion region, and uncomfortable reactions, such as
dizziness, nausea or vomiting, aggravation of com-
plaint, malaise, fever and numbness, were not observed
in the heat-sensitive moxibustion group. Meanwhile,
several patients in the control group had adverse reac-
tions. The most common adverse reactions to Seretide
are upper respiratory tract infection, mouth infection,
nausea, headache, muscle and bone pain, and bronchi-
tis.31,32 The superiority of heat-sensitive moxibustion is
manifested in its safety. Large-scale surveys have provid-
ed evidence that moxibustion is a relatively safe treat-
ment.33
To our knowledge, this is the first randomized con-
trolled trial with large sample to compare the curative
effect of heat-sensitive moxibustion and Western Medi-
cine on asthma. Published studies have methodological
deficiencies, including deficient randomization descrip-
Variable
Observed ACT score
Before treatment
After half a month of treatment
After 1 month of treatment
After 2 months of treatment
After 3 months of treatment
3-month follow-up visit
6-month follow-up visit
Experimental group
Mean
15.10
17.86
19.54
20.65
21.60
21.35
21.29
SD
4.05
3.69
3.68
3.22
2.77
2.75
2.88
Control group
Mean
15.70
18.54
19.81
20.98
21.20
20.47
20.35
SD
3.78
4.13
3.99
3.27
3.61
3.58
3.72
t test a
1.30
－1.18
－0.31
－0.52
3.15
2.68
4.42
P value
0.19
0.14
0.56
0.39
0.0002
0.0009
0.000 03
Mean difference, MD
(95% CI)
－0.60 (－1.50, 0.30)
－0.68 (－1.58, 0.22)
－0.27 (－1.17, 0.63)
－0.33 (－1.08, 0.42)
0.40 (－1.34, 1.14)
0.88 (0.14, 1.62)
0.94 (0.17, 1.71)
Table 2 Comparison of ACT scores at different time-points between groups
Notes: experimental group was treated with heat-sensitive moxibustion; control group was treated with fluticasone/salmeterol (Seretide).
ACT: asthma control test. Bonferroni adjustment t-test was used for group differences. The adjusting of P-values was 0.008.
Table 3 Comparison of FEV1 and PEF between groups at each time point
Lung function
Observed FEV1 (L)
Before treatment
After 3 months of treatment
6-month follow-up visit
Observed PEF (m/s)
Before treatment
After 3 months of treatment
6-month follow-up visit
Experimental group
Mean
74.90
87.29
83.34
72.81
86.16
84.89
SD
16.70
17.44
22.29
22.25
21.27
23.01
Control group
Mean
75.10
83.39
80.52
73.83
81.64
80.01
SD
18.50
22.29
20.93
24.33
26.27
25.75
t test a
0.37
1.86
1.69
0.10
2.07
2.19
P value
0.92
0.035
0.042
0.71
0.011
0.0012
Mean difference, MD
(95% CI)
－0.20 (－4.27, 3.87)
3.90 (－0.72, 8.52)
2.82 (－2.33, 7.97)
－1.02 (－6.40, 4.36)
4.52 (－1.00, 10.04)
4.88 (－0.76, 10.52)
Notes: experimental group was treated with heat-sensitive moxibustion; control group was treated with fluticasone/salmeterol (Seretide).
FEV1: forced expiratory volume in 1 second; PEF: peak expiratory flow.
Figure 2 Comparison of ACT scores at different time-points
ACT: asthma control test. a: 3-month follow-up visit; b:
6-month follow-up visit.
0 0.5 1 2 3 3a 6b
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tions, no concealment of therapeutic plan, data hetero-
geneity between groups, and different periods of fol-
low-up visits. Unlike previous studies on moxibustion,
our study required participating therapists to have cor-
responding medical education and TCM clinical prac-
tice before performing treatment according to a series
of strict standards. In addition, our study used central
randomization to ensure adequate concealment of
group assignment. Both evaluation and statistical analy-
sis were carried out blindly. High quality follow-up vis-
its were an important guarantee for the quality of our
trial.
However, it was impossible for doctors to conduct a
blind manipulative intervention method in this study.
Zhao et al 34 has developed a moxa cone fixed to a spe-
cial base to carry out sham or real moxibustion. Sham
moxibustion is identical to real moxibustion in the
shape, burning process, and residue of moxa cone but
distinct in only the production of heat and smoke and
isolation from skin. Of course, such a method is suit-
able for direct moxibustion. It is necessary for experi-
enced therapists to carry out heat-sensitive moxibus-
tion, an indirect moxibustion. Furthermore, it is very
easy for bronchial asthma patients to distinguish
heat-sensitive moxibustion from Seretide. However, it
is possible for patients to carry out a blind method.
Acupoints unrelated to asthma treatment can be select-
ed for sham moxibustion in the control group. Mean-
while, a placebo could be taken in real moxibustion
group. We intended to try the blind method in future
trials.
In our trial, we selected acupoints in the back, which
are used to treat bronchial asthma and other lung dis-
eases according to TCM theory. For example, Fei Shu
(BL 13) on the Bladder Meridian of Foot-Taiyang, is
used to treat bronchitis, asthma, pleurisy, and night
sweating and can regulate lung Qi, improve lung func-
tion, and build Stomach Qi. Some experimental stud-
ies have indicated that the mechanism of moxibustion
may be related to adjusting the release of inflammatory
substances in the lung, improving respiratory tract
spasms, and inhibiting respiratory tract inflamma-
tion.33-35 A study of 32 patients with both asthma and
rheumatoid arthritis showed the effects of acupuncture
and moxibustion on immunoglobulin.36,37 A study in
1995 of 94 patients with bronchial asthma showed
that acupuncture and moxibustion can affect the ner-
vous and immune systems, cause metabolic changes,
and effectively reduce the sensitivity and reactivity of
bronchioles. In other words, acupuncture and moxibus-
tion can reduce the reactivity of bronchioles to asth-
ma-inducing factors.37,38 Although studies from China
have investigated the mechanisms of moxibustion on
the nervous system,39 further study is still necessary.
Because adverse reactions caused by long-term use of
asthma drugs can influence their continuous use, other
treatment courses are necessary. This study has demon-
strated that the curative effect of heat-sensitive moxi-
bustion is not inferior to that of Seretide on asthma.
Therefore, our study has clinical significance for pro-
viding a potential non-drug therapy to control asthma.
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